Fierce JPM Week 2025 - Virtual: Full Schedule

10:20am EST

Panel: Cell & Gene Therapy: Challenges, Trends and Technologies

Wednesday January 22, 2025 10:20am - 11:00am EST

With advancements in platform technologies and automation, the cell and gene therapy space is poised for changes. During this panel discussion, industry leaders will explore challenges and share insights on navigating regulatory hurdles, optimizing manufacturing and leveraging emerging technologies to address broader disease states.

Moderators

Fraiser Kansteiner

Staff Writer, Fierce Pharma

Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser... Read More →

Speakers

Christopher Arendt, Ph.D.

Chief Scientific Officer, Head of Research, Takeda

Based at Takeda’s Cambridge, Massachusetts, R&D campus, Christopher Arendt is responsible for oversight of Takeda’s Research and Early Development portfolio across Takeda’s core therapeutic areas of Gastroenterology andInflammation, Oncology, and Neuroscience. Prior to his current... Read More →

Kevin Forrest, Ph.D.

Co-Founder and former CEO, Kate Therapeutics

Kevin Forrest, Ph.D., was most recently co-founder, President, and CEO of Kate Therapeutics, a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. Dr. Forrest led KateTx from inception through its acquisition... Read More →

Dr. Nadir Mahmood

President, Nkarta

Dr. Nadir Mahmood serves as President of Nkarta, where he is responsible for driving the company’s strategic focus, business excellence, and technical success. He previously served as the Chief Executive Officer of Rezo Therapeutics, a private-stage drug discovery company. Prior... Read More →

Cindy Perettie

Executive Vice President, Kite, a Gilead Company

Cindy Perettie serves as Executive Vice President of Kite, a Gilead Company, and is responsible for overseeing the cell therapy business. Cindy joined Kite in 2023 with more than 20 years of scientific and commercial leadership experience in global biopharmaceutical organizations... Read More →

Shehnaaz Suliman, M.D., MBA, M.Phil.

Chief Executive Officer, ReCode Therapeutics

Shehnaaz Suliman, M.D., MBA, M.Phil., serves as Chief Executive Officer of ReCode Therapeutics, a leading privately held biotechnology company powering the future of genetic medicines with a next-generation lipid nanoparticle platform. Lead programs are in primary ciliary dyskinesia... Read More →

Wednesday January 22, 2025 10:20am - 11:00am EST
Virtual

Panel

12:05pm EST

Panel: Unlocking the Power of Healthcare Data: Advancing Access and Connectivity to Drive Patient Outcomes

Wednesday January 22, 2025 12:05pm - 12:45pm EST

Virtual

As healthcare embraces a more connected future, the need for real-time, global data access has become vital to bridging gaps in patient care and streamlining drug development. This panel delves into the challenges and opportunities in democratizing healthcare data, with a focus on integrated solutions and strategies that address data fragmentation and enable swift access to diverse patient and provider demographics. Join us to discover how democratizing healthcare data will shape the future of global patient care and catalyze advancements in the biopharma industry.

Moderators

Stephanie Butler

Senior Conference Production Director, Fierce Life Sciences

Stephanie Butler is a Senior Conference Production Director with Fierce Life Sciences. Previously, Ms. Butler was a Division Manager at the American Conference Institute where she was responsible for the for the creation and development of legal and business conferences in the Pharmaceutical/Life... Read More →

Speakers

Jeffrey Helterbrand, Ph.D.

SVP, Data Sciences, Roche

Jeff is a Senior Vice President in PD Data Sciences (formerly Biometrics) at Roche. Data Sciences at Roche includes statisticians, patient-centered outcomes researchers, statistical programmers, clinical data managers, and medical data and information solution teams. Jeff is a member... Read More →

Ariel Katz

CEO and Co-Founder, H1

Ariel Katz is the CEO and Co-founder of H1, the connecting force for global HCP, clinical, scientific and research information. H1 works with the top Pharma and BioTech companies to deliver AI-powered insights to Medical Affairs and Clinical Operations to accelerate the discovery... Read More →

Ebony Dashiell-Aje, PhD

Executive Director & Head of Patient Centered Outcomes Science in Clinical Development, BioMarin

Ebony Dashiell-Aje, PhD is the Executive Director & Head of Patient Centered Outcomes Science in Clinical Development, at BioMarin. Dr. Dashiell-Aje is a leading expert in clinical outcome assessment (COA) and digital health technology development and optimization, including related... Read More →

Phil Johnson

Chief Commercial Officer, Evidation Health

Phil Johnson is Chief Commercial Officer at Evidation, applying real-world data to advance patient-centric health research and accelerate drug development. Leveraging Evidation’s community of over 5 million individuals and its innovative capabilities in direct-to-patient, longitudinal... Read More →

Wednesday January 22, 2025 12:05pm - 12:45pm EST
Virtual

Panel

1:20pm EST

Panel: Biotech Markets and IPOs: Trends from 2024 and Projections for 2025

Wednesday January 22, 2025 1:20pm - 2:00pm EST

Virtual

The biotech market made a comeback in 2024, recovering from a slump a year earlier. What will the IPO window look like in 2025? During this panel discussion, we will examine the performance of companies that went public in the second half of 2024 and how their success or challenges are impacting other startups’ decisions on whether to go public themselves

Moderators

Gabrielle Masson

Associate Editor, Fierce Biotech

Gabrielle Masson is an associate editor for Fierce Biotech. Prior to Fierce, she worked at Becker's Hospital Review, where she reported on public health and the pandemic. Gabrielle graduated from the University of Wisconsin-Madison after studying creative writing and criminal justice... Read More →

Speakers

Maha Katabi

General Partner, Sofinnova Investments

Troy Ignelzi

CFO, Rapport Therapeutics

Troy has nearly two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Troy has raised an impressive $4 billion-plus in capital for life science companies. Most recently, he was Chief Financial Officer at Karuna Therapeutics... Read More →

Chirag D. Surti

Executive Director, Morgan Stanley

Jeffrey Finer, MD, PhD

Chief Executive Officer and Co-Founder, Septerna

Jeffrey Finer, MD, PhD, is the Chief Executive Officer and Co-Founder at Septerna. Dr. Finer has more than 35 years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several first-in-class drugs into clinical... Read More →

Wednesday January 22, 2025 1:20pm - 2:00pm EST
Virtual

Panel

Qtag Featured

10:10am EST

Panel: Our AI future: A Sector-by-Sector Breakdown

Thursday January 23, 2025 10:10am - 10:50am EST

Virtual

As AI and machine learning continue to reshape biotech, medtech, and pharma, this panel will explore the latest trends, challenges, and opportunities for AI-driven advancements across these sectors. Experts will take an in-depth look at how AI is streamlining processes—from drug discovery to medical device development—and share real-world examples of its impact on patient care.

Moderators

Zoey Becker

Staff Writer, Fierce Pharma

Zoey Becker is a staff writer for Fierce Pharma. She joined the Fierce team in 2022 after interning at the Cincinnati Herald. Zoey is a graduate of Miami University, where she earned a degree in journalism as well as sociology. She currently resides in Chicago with her two goldfi... Read More →

Speakers

Sai Jasti

Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D

Sai Jasti is Head of Data Science and AI for Bayer Pharma R&D. In this capacity, Sai is responsible for driving Digital, Data and Analytics for Pharma R&D. He is passionate about helping scientists discover transformative medicines faster and driving innovation using Machine learning... Read More →

Dr. Maria Luisa Pineda

Envisagenics, CEO and Co-Founder

Dr. Maria Luisa Pineda is the CEO and co-founder of Envisagenics. Dr. Pineda embarked on her career in STEM as a high school Intel International Science Fair winner in Miami after immigrating from Colombia in 2001. She received her doctorate from Cold Spring Harbor Laboratory School... Read More →

Lars Fogh Iversen, PhD

Senior Vice President, Digital Science & Innovation, Novo Nordisk A/S

Lars has held his current role since early 2022 and is responsible for accelerating the digital transformation of R&ED and driving scientific innovation beyond the limits of human cognition through the purpose of DSI.A long-time employee of Novo Nordisk, Lars has held a variety of... Read More →

Alexandra Goncalves

VP & Head of Digital Health, Bristol Myers Squibb

Dr. Alexandra Goncalves is an internationally recognized academic cardiologist with a business acumen and serves as VP and Head of Digital Health at Bristol Meyers Squibb, leading DH business strategy and execution across all company portfolio, from clinical development to commercialization.Prior... Read More →

Najat Khan, PhD

Chief R&D Officer and Chief Commercial Officer, Recursion

Dr. Najat Khan is Recursion’s Chief R&D and Chief Commercial Officer, adding deep expertise in pharmaceutical innovation and data science to its leadership team. Before joining Recursion, she served as the Chief Data Science Officer and Global Head of Strategy and Portfolio Organization... Read More →

Thursday January 23, 2025 10:10am - 10:50am EST
Virtual

Panel

12:15pm EST

Panel: Global Clinical Trials: Overcoming Barriers and Seizing Opportunities in an International Landscape

Thursday January 23, 2025 12:15pm - 1:05pm EST

Virtual

As clinical trials expand across borders, sponsors face unique challenges that can slow progress and increase complexity. This panel will dive into the key hurdles holding sponsors back, from navigating varying regulatory requirements to overcoming cultural and language barriers. Industry experts will explore strategies to streamline regulatory approvals, improve trial efficiency across diverse regions, and leverage cultural insights to enhance patient recruitment and retention. Join us for a deep dive into the opportunities and solutions driving the future of international clinical trials.

Moderators

Stephanie Butler

Senior Conference Production Director, Fierce Life Sciences

Speakers

Eric A. Hughes, MD, PhD

Executive Vice President of Global R&D, Chief Medical Officer, Teva Pharmaceuticals

Eric A. Hughes, MD, PhD, is Executive Vice President, Global R&D and Chief Medical Officer at Teva, overseeing a global organization responsible for the discovery, development, registration, medical affairs and patient safety activities for Teva’s generics, biosimilar and innovative... Read More →

Janet Hammond, MD, PhD

Chief Development Officer, Atea Pharmaceuticals

Janet is an expert in virology with a proven track record in antiviral therapeutic drug discovery and development. Janet has more than 20 years of broad and deep pharmaceutical and biopharmaceutical experience including clinical development program leadership and responsibilities... Read More →

Irfan Qureshi

Chief Medical Officer, Biohaven, Ltd

Irfan Qureshi, M.D., Chief Medical Officer, Biohaven (NYSE: BHVN) is a Board-certified neurologist with more than 20 years of experience in industry, academia, and patient care.Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing... Read More →

Judith Ng-Cashin, M.D.

Chief Medical Officer, Novotech

Judith Ng-Cashin, M.D. joined Novotech in 2023 as its Chief Medical Officer. With a rich background encompassing over two decades in the international pharmaceutical, biotech, and CRO sectors, Dr. Ng-Cashin plays a pivotal role in shaping Novotech's global multi-regional later-phase... Read More →

Keiko Oishi

President & COO, CMIC HOLDINGS Co., Ltd.

Thursday January 23, 2025 12:15pm - 1:05pm EST
Virtual

Panel

1:40pm EST

Panel: Pharma’s Financial Landscape: Revenue Trends, M&A Strategies, and Patent Expirations

Thursday January 23, 2025 1:40pm - 2:20pm EST

Virtual

With some of the industry’s top drugs moving toward patent cliffs later this decade, Big Pharma dealmakers have remained active despite economic uncertainties. The 2024 buyouts of Catalent, Alpine Immune Sciences and CymaBay Therapeutics—among others—showed that drugmakers were willing to strike deals for the right assets at the right prices. As the industry navigates the Inflation Reduction Act and other factors, biopharma leaders and venture capitalists on this panel will share their expectations for the year ahead.

Moderators

Fraiser Kansteiner

Staff Writer, Fierce Pharma

Speakers

Adam Pearson

Chief Strategy Officer, Astellas

As Chief Strategy Officer of Astellas Pharma, Adam Pearson plays a pivotal role in shaping the company’s corporate strategy, spearheading initiatives in business planning, the development and execution of Primary Focus strategies, business partnerships, Rx+ business creation, Patient... Read More →

Greg Graves

Senior Partner, McKinsey & Company

Greg is a senior partner in McKinsey’s Life Sciences Practice, where he leads the practice’s strategy and corporate finance work. Greg focuses on defining winning corporate strategies in the face of industry disruption and market uncertainties. He works with companies across the... Read More →

Christine (Chris) Fox

Executive Vice President, U.S. Commercial, Teva Pharmaceuticals

Christine (Chris) Fox was appointed Executive Vice President, U.S. Commercial on November 20, 2023, leading all commercial activities for Teva in the U.S., including Teva’s generics, biosimilars and innovative medicines business. Chris brings more than 30 years of healthcare industry... Read More →

Jeb Keiper

CEO & President, Nimbus Therapeutics, LLC

Jeb Keiper, MS, MBA, is CEO and president of Nimbus Therapeutics, LLC, a Boston-based biotechnology company focused on developing breakthrough medicines for patients through precision small molecule design. Jeb has overseen the discovery and development of multiple programs into clinical... Read More →

Anis Ha

SVP, Deputy General Counsel Transactions and Contracting, Eli Lilly and Company

Anis Ha serves as the Senior Vice President / Deputy General Counsel of Transactions and Contracting at Eli Lilly and Company. Anis is a broadly experienced executive with global pharmaceutical, biotechnology, and law firm experience. In his current role at Eli Lilly, Anis leads a... Read More →

Thursday January 23, 2025 1:40pm - 2:20pm EST
Virtual

Panel

3:20pm EST

The Future of Oncology: Key Investment Areas and Advancements in Treatment Methodologies

Thursday January 23, 2025 3:20pm - 4:00pm EST

Virtual

ADCs, bispecifics and radiopharmaceuticals are making waves in oncology treatment. Practice-changing clinical data have spurred major investments and deals. At the same time, much-touted cell therapies have run into real-world issues such as capacity and infrastructure limitations. During this panel, we will explore what’s next for these trends as the industry continues its efforts to advance patient care.

Moderators

Angus Liu

Deputy Editor, Fierce Pharma

Angus is a deputy editor with Fierce Pharma. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to Medill, he worked as a... Read More →

Speakers

Bassil I. Dahiyat, Ph.D.

President & Chief Executive Officer, Xencor

Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He is the co-founder of Xencor and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in creating a diverse clinical-stage portfolio... Read More →

Puja Sapra

Senior Vice President, Biologics Engineering and Oncology Targeted Discovery, AstraZeneca

I serve as Vice President, Tumour Targeted Delivery, Early Oncology. In my current role, I lead the research group dedicated to the discovery and preclinical development of targeted cancer therapeutics and novel delivery mechanisms that selectively attack cancer cells while sparing... Read More →

Hesham Abdullah

Senior Vice President, Global Head Oncology, Research & Development, GSK

Hesham Abdullah is a seasoned physician-scientist who uniquely combines a clinician’s understanding of the impact cancer has on patients with deep expertise in identifying transformational opportunities to improve cancer treatment and care.As the head of GSK’s global oncology... Read More →

Teresa Bitetti

President of the Global Oncology Business Unit and a member of the Executive Team, Takeda

Teresa Bitetti is President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Teresa leads all aspects of Takeda’s multi-billion-dollar... Read More →

Mai-Britt Zocca, Ph.D.

Founder and Chief Executive Officer, IO Biotech

Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech spinouts. Her focus on translational and clinical immune oncology has led to the development of important investigational immunotherapies for a variety of cancer... Read More →

Thursday January 23, 2025 3:20pm - 4:00pm EST
Virtual

Panel

Qtag Featured

10:10am EST

Post-Election Briefing: Federal Healthcare Policy in the Next Four Years

Friday January 24, 2025 10:10am - 10:50am EST

Virtual

President-elect Donald Trump's return to the White House and Republican's control of Congress could bring significant changes to healthcare policy in the next four years. The Trump administration could make changes to the Affordable Care Act and also reshape the Medicare and Medicaid programs. Trump also has signaled an interest in tackling the rise in chronic illnesses. What will the Trump administration have in store for the evolution of value-based care and healthcare AI regulation? Hear from policy experts who will dive into what a second Trump term will mean for your business.

Moderators

Heather Landi

Executive Editor, Fierce Healthcare

Heather Landi is an executive editor at Fierce Healthcare, responsible for the entire daily Fierce Healthcare brand and related team of editors. She previously served as senior editor, overseeing the team’s coverage of health IT and digital health news. With more than nine years... Read More →

Speakers

Leigh Burchell

Vice President, Policy and Public Affairs, Altera Digital Health

Leigh Burchell directs the Policy & Government Affairs function for Altera Digital Health, including legislative advocacy and regulatory interpretation and comment. Burchell is also active in many industry associations, including the Electronic Health Record Association (EHRA), where... Read More →

Dr. Sanjay Doddamani

Founder and CEO, Guidehealth

Dr. Sanjay Doddamani is the Founder and CEO of Guidehealth, a company focused on AI-powered healthcare services and value-based care. Guidehealth has been recognized as a leader in value-based managed services and currently supports over half a million lives across four states and... Read More →

Judy Stecker

Executive Vice President, Burson

Judy Stecker is an Executive Vice President in Burson’s Corporate Affairs practice. She is a known, trusted strategic advisor with more than 15 years of experience managing diverse teams focused on strategic communications, policy, external affairs, crisis communications, government... Read More →

Friday January 24, 2025 10:10am - 10:50am EST
Virtual

Panel

11:10am EST

Medicare Advantage: Is the Bubble about to Burst?

Friday January 24, 2025 11:10am - 11:50am EST

Virtual

Medicare Advantage insurers have seen rapid growth over the past decade, with massive profits in tandem. However, cuts to federal payments, a spike in utilization and other challenges have turned this space into a huge headache for health plans. During this panel, you’ll hear from experts in the industry and beyond about what’s next for Medicare Advantage, and if the sector’s hot momentum may be over.

Moderators

Paige Minemyer

Senior Writer, Fierce Healthcare

Paige Minemyer is a senior writer at Fierce Healthcare, overseeing the team’s coverage of payer trends and news from across the country. Since joining the Fierce team, she’s covered the spectrum of the healthcare industry, including providers, technology and policy. She has also... Read More →

Speakers

Greg Gierer

Principal, Healthcare Management Associates

Greg Gierer is a health policy expert with more than 20 years of experience in Washington, DC with demonstrated success in advocating before the Congress, federal agencies, state governments and policymakers. He has expertise in the federal legislative and regulatory policy process... Read More →

Dawn Maroney

President, Markets of Alignment Health; CEO, Alignment Health Plan

With more than 35 years in healthcare, Dawn Maroney is highly regarded as an industry expert and pioneer in positioning healthcare organizations for success in the challenging Medicare, Medicaid and underserved markets.In her current role as president, markets of Alignment Health... Read More →

Friday January 24, 2025 11:10am - 11:50am EST
Virtual

Panel